Mark E. Anderson

The paper develops a CaMKII biosensor for high-throughput screening and identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor effective in preventing atrial fibrillation.

This paper shows that excessive O-GlcNAcylation causes heart failure and sudden death in mice, while reducing it protects against cardiac stress.

This study shows mitochondrial CaMKII activation leads to metabolic reprogramming, energetic insufficiency, and dilated cardiomyopathy, with potential therapeutic targets identified.

This study shows that O-GlcNAcylation and oxidative stress via CaMKII contribute to atrial fibrillation in type 1 and type 2 diabetes through distinct mechanisms.